

## Diaceutics PLC

### Purchase of Shares and PDMR Shareholding

**New York, Belfast and London, 31 January 2025** - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, announces that on 30 January 2025, Graham Paterson, the Senior Independent Non-Executive Director of Diaceutics PLC, purchased 11,643 ordinary shares of £0.002 in the capital of the Company ("Ordinary Shares") at a price of 137.5 pence per Ordinary Share. As a result of the purchase, Graham's shareholding is 85,141 Ordinary Shares, representing approximately 0.10% of the Company's issued share capital.

**Enquiries:**

**Diaceutics PLC**

Ryan Keeling, Chief Executive Officer  
Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500  
investorrelations@diaceutics.com

**Canaccord Genuity Limited (Nomad & Broker)**

Simon Bridges, Andrew Potts, Harry Rees

Tel: +44 (0)20 7253 8000

**About Diaceutics**

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
<b>1 Details of the person discharging managerial responsibilities/person closely associated</b>		
a.	Name	Graham Paterson
<b>2 Reason for notification</b>		
a.	Position/Status	Non-Executive Director
b.	Initial notification/ Amendment	Initial
<b>3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument  Identification Code	Ordinary shares of £0.002 each  ISIN: GB00BJQTV64				
b.	Nature of the transaction	Purchase				
c.	Price(s) and volume(s)	Share purchase: <table border="1" data-bbox="507 488 949 627"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>137.5 p</td> <td>11,643</td> </tr> </tbody> </table>	Price(s)	Volume(s)	137.5 p	11,643
Price(s)	Volume(s)					
137.5 p	11,643					
e.	Date of the transaction	30 January 2025				
f.	Place of the transaction	AIM Market of the London Stock Exchange				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFIFLALLILVIE